• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Providers

Latest News

Pooled data demonstrated elinzanetant's efficacy overall and across BMI and smoking status subgroups. | Image credit: Monkey Business - stock.adobe.com
Elinzanetant Effective for Menopause Symptoms Across BMI, Smoking Status

April 17th 2025

Elinzanetant significantly reduced the frequency and severity of vasomotor symptoms, known as hot flashes, compared with placebo across body mass index (BMI) and smoking status subgroups.

Patients who stopped adjuvant immunotherapy less than 12 months following metastatic melanoma resection did not experience inferior outcomes. | anna.stasiia - stock.adobe.com
Early Adjuvant Immunotherapy Discontinuation Does Not Affect Melanoma Recurrence Risk

April 17th 2025

Missy Hopson, PhD
Empowering Teams Begins With Human Connection: Missy Hopson, PhD

April 16th 2025

Hospital and ED use were similar at the individual and neighborhood levels, but the use of outpatient services differed. | Image credit: Spiroview Inc - stock.adobe.com
Individual, Neighborhood-Level Social Risk Indicators Provide Distinct Health Care Use Insights

April 15th 2025

In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com
Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

April 15th 2025

More News

© 2025 MJH Life Sciences
AJMC®
All rights reserved.